Introduction
Cholangiocarcinoma (CCA) is an uncommon tumor that constitutes ,2% of all human malignancies. 1 Perihilar cholangiocarcinoma (pCCA) is a subtype of CCA that locates at the area between the insertion of the cystic duct into the common bile duct and the second-degree bile ducts. It accounts for approximately two-thirds of all CCAs. 2, 3 pCCA possesses a peculiar growth behavior that spreads longitudinally and frequently invades major vascular structures. It is a relatively slow-growing cancer and is usually small at clinical presentation. Therefore, it is usually too advanced for radical surgery after being diagnosed. This makes pCCA a devastating cancer with a median survival of ,1 year if untreated.
Complete resection is recognized as an effective therapy for pCCA. It is found that 5-year survival and median survival among patients with a complete resection range from 27% to 45% and from 27 to 58 months, respectively. [4] [5] [6] [7] Prognosis of pCCA is still poor despite great improvement. Moreover, locoregional recurrence is found in ~60% of patients undergoing curative resection for pCCA, whereas distant submit your manuscript | www.dovepress.com
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leng et al metastases are seen in almost 40% of cases. 8 As such, radiotherapy has been proposed and, to a varying degree, is used currently as adjuvant therapy for resected pCCA. However, it remains controversial. [9] [10] [11] [12] [13] [14] [15] [16] Several research studies have shown an improved survival benefit with adjuvant radiation therapy (RT) among patients undergoing curative intent operations. 9, [13] [14] [15] 17 By contrast, some other studies did not detect a survival benefit from adjuvant RT. 10, 12 It is possible that the debate is largely attributed to the overrepresentation of pCCA patients with adverse tumor characteristics in the cohorts that received adjuvant RT. It is reported that patients with positive resection margin, lymph node (LN) metastasis, and high histological grade were more likely to receive adjuvant RT. 12, 13, 15 The selection bias in the receipt of adjuvant RT might result in inaccurate interpretation of the efficacy of adjuvant RT.
This study used the Surveillance, Epidemiology and End Results (SEER) database to evaluate the effect of adjuvant RT on the survival outcome of radically resected pCCAs. In order to minimize the selection bias in patients received adjuvant RT, propensity score matching was applied. The present study could provide the basis for the optimal therapeutic approach to pCCA.
Patients and methods
The SEER database represent 28% of the US population, and the 18 registries participating in the SEER program capture ~97% of incident cancers. 18, 19 The SEER database data are publicly available. Use of the SEER database data does not require informed consent, and this study was approved by the ethics committee of the Second Affiliated Hospital of Harbin Medical University and Foshan Hospital Affiliated to Southern Medical University.
Several predefined variables were used to screen eligible patients: "CS SCHEMA v0204+" of "008-Bile Ducts Perihilar," "Age at diagnosis" of $20, and "Year of diagnosis" ranging from 1988 to 2009. The International Classification of Diseases for Oncology, 3rd Edition (ICD-0-3) codes were used to identify cases of pCCA. pCCA was defined as tumors with histological codes of 8010, 8020, 8040, 8070, 8041, 8140, 8144, 8160, 8161, 8162, 8163, 8260, 8310, 8480, 8490, and 8560 with a topographic code of C24.0 and C22.1. Patients without microscopic diagnostic confirmation, unknown diagnostic confirmation, or diagnosed on autopsy were excluded. Patients were also excluded if they survived ,2 months, had unknown radiotherapy information, presented with distant metastasis, or with a surgery code not consistent with surgical resection. Figure 1 depicts a flowchart regarding patient selection for the study cohort.
Briefly, the cohort included all patients aged $20 years who had a histological diagnosis of pCCA who underwent curative intent surgical resection with known disease stage and radiation status between 1988 and 2009.
Data collected for each patient included patient demographics (age at diagnosis, race/ethnicity, gender, year of diagnosis, and marital status), tumor characteristics (tumor size, grade, and tumor stage), and treatment modality (sequence of radiation and status of adjuvant RT). Tumor stage was reported for only years 2004 and later. For patients from 1988 to 2003, tumor stage was derived from the extent of the primary tumor. To facilitate the current analysis, tumor stage was classified into two categories: localized disease (stages T1-T2) and regional disease (stages T3-T4 and/or node positive). According to the SEER classification of surgery, radical resection was defined as partial or total removal of primary site plus partial or total removal of other organs. Limited resection was defined as either partial or total operative removal of only the primary site.
Propensity score matching
Because of the nonrandom distribution in the receipt of adjuvant RT, the survival outcomes could be influenced by the selection bias. A propensity score is defined as the probability of being assigned to adjuvant RT group or surgeryalone group based on the clinicopathologic characteristics. 20 Propensity score matching using the greedy matching algorithm was used to compare the survival outcomes of patients treated with and without adjuvant RT after controlling for selection bias. In the calculation of the propensity scores, a nonparsimonious logistic regression model with the treatment of interest (adjuvant RT) as the outcome measure was used considering predefined baseline covariates, including year of diagnosis, gender, age at diagnosis, race, tumor extent, LN status, tumor size, and extent of surgery. 21 In the matched population, univariate and multivariate analyses for prognostic factors were conducted.
statistical analysis
Overall survival (OS) and cancer-specific survival (CSS) were the primary and secondary outcomes of interest, respectively. OS was calculated from the date of diagnosis to the date of death of any cause. CSS was defined as the time of diagnosis until pCCA-related death. The chi-square test was used to compare the clinical and demographic factors between patients grouped by categorical variables. Survival outcomes before and after propensity score matching were conducted using the Kaplan-Meier method and compared using the log-rank test. The Cox proportional hazard model 
Results
Patient characteristics
Between 1988 and 2009, 1,917 patients underwent resection for pCCA and met inclusion criteria; 762 (39.7%) patients received adjuvant RT. The median age of the entire cohort was 67 years (interquartile range 58-74 years). Most patients were male (n=1,157; 60.4%) and white (n=1,513; 78.9%). The clinicopathologic characteristics between the two groups are presented in Table 1 . Patients receiving adjuvant RT versus surgery alone were younger (65 vs 68 years, P,0.001), had more advanced tumor stage (86.0% vs 76.7%, P,0.001), and had more positive LN (43.8% vs 32.2%, P,0.001).
survival outcomes before propensity score matching
In the unmatched population (n=1,917), 1,642 patients died at the end of follow-up. The unadjusted median survival was 23 months, and 5-year rate of OS was 24.5%. There were 1,162 pCCA-related death events, and the median and 5-year rates of CSS were 17 months and 7.7%, respectively. Kaplan-Meier curves of OS and CSS before propensity score matching are presented in Figure 2 . In both OS and CSS, there were no significant differences between the adjuvant RT (n=762) and surgery alone (n=1,155) groups. Median OS for patients receiving adjuvant RT compared with Prognostic effect of adjuvant rT after propensity score matching The propensity score matching was able to create a balanced population including adjuvant RT group (n=651) and surgeryalone group (n=651). Table 1 lists the details of the balance before and after propensity score matching, noting that the potential selection bias in the receipt of adjuvant RT was minimized.
Kaplan-Meier curves of OS and CSS after propensity score matching are presented in Figure 3 . The median and 5-year rates of OS for the adjuvant RT and surgery-alone groups were 22 months and 24.2% and 23 months and 24.6%, respectively. The median and 5-year rates of CSS for the adjuvant RT and surgery-alone groups were 17 months and 8.4% and 18 months and 9.4%, respectively. Table 2 shows the results of the univariate analyses for OS and CSS. Age (P,0.001), tumor stage (P,0.001), LN status (P,0.001), tumor grade (P=0.005), and tumor size (P,0.001) were associated factors of OS. For CSS, year Figure 2 Kaplan-Meier analysis of (A) overall and (B) cancer-specific survival of the adjuvant RT (n=762) and surgery alone (n=1,155) groups before propensity score matching. Abbreviation: rT, radiation therapy.
Figure 3
Kaplan-Meier analysis of (A) overall and (B) cancer-specific survival of the adjuvant RT (n=651) and surgery alone (n=651) groups after propensity score matching. Abbreviation: rT, radiation therapy. (Table S1 ).
Discussion
The present study found no significant survival benefit from adjuvant RT for patients with resected pCCA. Advanced tumor stage, frequent LN metastasis, and poor to undifferentiated histologic grade were tumor characteristics significantly associated with poorer OS and CSS. Patients with adverse tumor characteristics also did not have significantly superior survival with adjuvant RT as compared to those without high-risk features. These data suggest that adjuvant RT should not be routinely used to treat patients with pCCA outside research trials. pCCA is an uncommon tumor with a poor prognosis. It still remains difficult to achieve negative microscopic margins, which may offer the only hope of cure and longterm survival for pCCA. It is reported that the primary site of recurrence following complete resection is usually locoregional in patients with pCCA (59%). 8 Thus, RT has frequently been recommended both as adjuvant therapy for resected patients and as primary treatment for unresectable patients. However, the role of locoregional therapy with adjuvant RT for pCCA remains controversial (Table S2 ).
To date, several studies have demonstrated that adjuvant RT was independently associated with improved survival in patients with pCCA. Todoroki et al found an increase in 5-year survival from 13% to 34% among patients receiving adjuvant RT. 13 One study in China reported a 10% increase in the 5-year survival among patients who received adjuvant RT, indicating that adjuvant external beam radiation was independently associated with better outcomes.
14 Another study from the Netherlands found that those who did not receive adjuvant RT had a median survival of 8 versus 24 months for patients who did undergo adjuvant RT. no survival benefit at 3 years was detected among patients with pCCA who received adjuvant RT. 12 Pitt et al also found that adjuvant RT had no effect on OS. 10 The interpretation of these reports is difficult because of a mixture of R0 and R1 resections and very small patient groups. In addition, it is found that patients with adverse tumor characteristics were more likely to receive adjuvant RT, which would result in cautious interpretation of the results.
This study found that 39.7% of patients received adjuvant RT after curative intent resection. As expected, receipt of adjuvant RT was not random but instead was related to specific clinical and pathological factors. Patients who underwent adjuvant RT had more adverse characteristics compared with patients who underwent surgery alone. In particular, it was found that factors including younger patient age, LN metastasis, and advanced tumor stage were all associated with a higher likelihood of receiving adjuvant RT. As such, it was clearly demonstrated that patients who received adjuvant RT were not comparable to patients who received surgery alone with regard to underlying tumor biology. Therefore, it is not surprising that with nonpropensity-matched analyses, patients receiving adjuvant RT had worse 5-year OS. The present study is important because it used propensity score matching to more fully control for baseline differences in the two groups. Using propensity score matching, two groups of patients with similar baseline characteristics were identified, which ultimately made the present analysis much more effective. In the univariate analysis, adjuvant RT failed to improve either OS or CSS in matched pCCA patients after surgical resection. Accordingly, the efficacy of adjuvant RT in local tumor control was questionable. Although multiple high-risk tumor characteristics were controlled, multivariate analysis in the matched population was also unable to establish a survival benefit from adjuvant RT. Taken together, the data suggested that adjuvant RT had no effect on survival of patients with resected pCCA.
There are several potential interfering factors that affect the results of this study to some degree. The first issue to be addressed is whether the dose of radiation was adequate. It is technically challenging to make rational and efficacious radiotherapy protocols for pCCA. Until now, no consensus has been established. Gonzalez Gonzalez et al suggested a dose .70 Gy because of the concept that CCA is a radioresistant tumor. 22 However, if radiation treatment with much higher dose caused serious toxicity that aborted treatment before completion, the patients would not benefit from adjuvant RT. Information regarding radiotherapy dose, radiotherapy plans, or whether radiotherapy courses were completed after initiation of therapy were not obtained. A second issue that may have inhibited the influence of radiation was whether radiation was given alone without concomitant sensitizing chemotherapy or not. The question of adjuvant chemotherapy still remains vague in pCCA. There are only few data for adjuvant chemotherapy in patients with CCA following curative intent surgery. 23 In general, there is no clear evidence for an OS benefit of adjuvant chemotherapy for not selected patients. 24 Finally, resection margin may have influenced survival outcomes. However, several studies reported that the effect of margin status on survival among patients with resected pCCA who received adjuvant chemoradiation therapy is minimal. 22, 25 The SEER database lacks its ability to capture margin status and chemotherapy regimens, but it seems to have little impact on this study. In addition, this study is the first large population-based study to investigate the role of adjuvant RT in pCCA. The potential selection bias in patients receiving adjuvant RT could be minimized by using propensity score matching. Although randomized evidence regarding adjuvant RT in resected pCCAs was absent, the result from this propensity score-matched analysis can provide insight into optimal treatment after curative intent surgery.
There are some other limitations to the current study. Although it is supposed that patients underwent surgical resection with curative intent, this important concept is still difficult to fully evaluate due to the lack of information regarding surgical details and margin status. The present study is also limited by the inability to obtain information regarding disease recurrence. Therefore, it is difficult to assess whether adjuvant RT is associated with better diseasefree survival and/or lower rates of local recurrence. Even though the SEER database is large, pCCA is an uncommon cancer and only 39.7% of patients underwent adjuvant RT. Hence, the size of this study cohort limited the ability to detect significant associations between adjuvant RT and clinical outcomes. The last limitation of this study is that propensity score match did not include performance status, which is highly prognostic.
Conclusion
RT is not associated with improved survival of patients with resected pCCA. The present study is considered important because the SEER database shows that a large proportion of patients with resected pCCA are currently being treated with adjuvant RT despite the lack of definitive evidence from randomized trials. Ideally, prospective randomized trials should be performed to verify the conclusion of this study. 
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